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Detection of antibodies to squalene III.
Naturally occurring antibodies to squalene in humans and mice
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Abstract
An ELISA-based assay is described for the measurement of antibodies to squalene (SQE) in human serum and plasma. The
assay was adapted from the previously described assay for murine antibodies to SQE (J. Immunol. Methods 267 (2002) 119).
Like the murine SQE antibody assay, the human antibody assay used sterile cell culture 96-well plates coated with SQE (20
nmol/well). Phosphate-buffered saline (PBS)–0.5% casein was used as both a blocking agent and dilution buffer. The assay has
a high through-put capacity and is reproducible and quantitative. This assay was used to evaluate samples from three different
human cohorts. The first cohort was retired employees of the United States Army Medical Research Institute of Infectious
Diseases (USAMRIID alumni). The mean age was 68 (N= 40; range 58–82). Most were vaccinated with the U.S. licensed
anthrax vaccine (AVA) and most had received several other vaccines through a USAMRIID special immunization program. The
second cohort was of similar age (N= 372; mean age 67; range 54–97) from the normal population of Frederick, MD and were
not vaccinated with AVA. The third cohort (N = 299) was from Camp Memorial Blood Center, United States Army Medical
Department Activities, Fort Knox, KY. (No additional volunteer information is available.) Using this new ELISA method,
antibodies to SQE were detected in all three of the cohorts. IgG antibodies to SQE were detected in 7.5% and 15.1% of the
samples from the USAMRIID alumni and Frederick cohorts, respectively. These differences were not significantly different
(v(1)
2 = 1.69, p = 0.19). In contrast, no IgG antibodies to SQE were detected in the Fort Knox cohort which is significantly
different than the Frederick cohort (v(1)
2 = 49.25, p < 0.0001). IgM antibodies to SQE were detected in 37.5% and 32.3% of the
samples from the USAMRIID and Frederick cohorts, respectively, but there was no significant difference between the cohorts.
0022-1759/$ - see front matter. Published by Elsevier B.V.
doi:10.1016/j.jim.2003.11.002
Abbreviations: ABTS, 2,2V-azino-di-(3-erthylbenzthiazoline-6-sulfonate); AVA, anthrax vaccine absorbed (licensed U.S. anthrax vaccine);
BSA, bovine serum albumin; FBS, fetal bovine serum; GEL, PBS–0.3% gelatin, pH 7.4; ISP, isopropanol; LDL, low density lipoprotein; PBS,
Dulbecco’s phosphate buffered saline without calcium and magnesium, pH 7.4; PVDF, polyvinyldiene fluoride; SQE, squalene; USAMRIID,
United States Army Medical Research Institute of Infectious Diseases; VLDL, very low density lipoprotein.
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In the Fort Knox cohort, 19.4% of the samples were positive for IgM antibodies to SQE, which was significantly different from
the Frederick cohort (v(1)
2 = 14.23, p = 0.0002). Although the age of the volunteers from the Fort Knox cohort is unknown, the
demographic of the donors at the blood bank volunteers is 85% 17–21 years of age. This suggested that the prevalence of
antibodies to SQE may increase with age. This was confirmed with mouse studies in which the presence of antibodies was
monitored as a function of time. No antibodies to SQE were detected in female BALB/c, B10.Br and C57BL/6 mice at 2 months
of age, but they reached a maximum prevalence with 100% and 89% of animals testing positive for IgG and IgM antibodies to
SQE, respectively, in the C57Bl/6 mice at 18 months of age. BALB/c and B10.Br mice also developed antibodies to SQE over
time, but were at a lower prevalence than those observed in the C57BL/6 mice. Thirty-five of the 40 volunteers in the
USAMRIID were vaccinated with AVA (mean no. doses = 26; range 3–47). Comparison of the prevalence of antibodies to SQE
from the AVA immunized group with the Frederick cohort revealed that there was no statistical differences for IgG (v(1)
2 = 2.3,
p = 0.13) or IgM (v(1)
2 = 0.33, p = 0.56). When the data from the USAMRIID and Frederick cohorts were combined and analyzed
for the presence of antibodies to SQE with respect to the sex of the volunteer, females (40.8%) were found to have a higher
prevalence of IgM antibodies to SQE than men (28.4%) (v(1)
2 = 6.59, p = 0.01). No significant difference was observed in the
prevalence for IgG antibodies to SQE in females (17.7%) and males (12.5%). We conclude that antibodies to SQE occur
naturally in humans; have an increased prevalence in females; are not correlated with vaccination with AVA; and appear to
increase in prevalence with age.
Published by Elsevier B.V.
Keywords: Squalene; Antibody detection; Enzyme-linked immunosorbent assay; Anthrax vaccine adsorbed
1. Introduction
Squalene (SQE) is a triterpenoid hydrocarbon oil,
C30H50 (2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-
tetracosahexene) (Fig. 1), that is widely produced in
plants and animals and is present in the food supply.
In mammals, SQE serves as a precursor for the
synthesis of cholesterol and steroid hormones (Gran-
ner, 1996; Mayes, 1996). SQE is synthesized in the
liver and in the epidermis of the skin by sebaceous
glands (Stewart, 1992). Both SQE and cholesterol are
transported in the very low density lipoprotein
(VLDL) and LDL (Miettien, 1982; Koivisto and
Miettinen, 1988).
Because it is a naturally occurring biodegradable
oil, SQE, and its hydrogenated derivative squalane,
each has been proposed as the oil component of oil-in-
water emulsions to be used as new adjuvants for
vaccines. Although not included in any vaccines
licensed in the United States, a SQE-containing emul-
sion is part of an influenza vaccine licensed in Italy
and has been given without adverse effects to
hundreds of thousands of people (Podda, 2001; Ott
et al., 2000). Numerous other human clinical trials for
influenza (Ott et al., 2000; Nicholson et al., 2001;
Gasparini et al., 2001), cytomegalovirus (Drulak et al.,
2000), hepatitis B (Heineman et al., 1999), papillo-
mavirus (Harro et al., 2001), HIV (Kahn et al., 1994;
Mitchell et al., 2002; McFarland et al., 2001; Cun-
ningham et al., 2001), and malaria (Stoute et al., 1997,
1998; Kester et al.,2001; Rickman et al., 1991) have
used SQE emulsions. Vaccine reactions were typically
mild. However, some moderate to severe reactions,
which can be attributed to other adjuvants in the
formulations, were reported (Kahn et al., 1994; Rick-
man et al., 1991; Stoute et al., 1997; Kester et al.,
2001). Furthermore, no adverse reactions were
reported following intravenous injection of humans
with chylomicron-like lipid emulsions containing
SQE (Relas et al., 2001).
Antibodies to SQE have generated great interest in
the popular press and have been the subject of U.S.
congressional hearings. This was initiated by a report
that antibodies to SQE were present in the serum of
sick Gulf War veterans, but not in healthy veterans
(Asa et al., 2000). The assay used in the later report
was severely criticized for technical reasons; includ-
ing lack of positive and negative controls (Alving and
Grabenstein, 2000). The Institute of Medicine con-
cluded that the reported results did not provide evi-
dence that antibodies to SQE were successfully
measured (Fulco et al., 2000). Using the same assay,
a report was published that claimed that military
service members who were sick following vaccination
with certain lots of the U.S. licensed anthrax vaccine
had antibodies to SQE (Asa et al., 2002). However, in
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blinded testing, no correlation was found between
individuals who received AVA and those in whom
purported antibodies to SQE were observed (Asa et
al., 2002). In view of the above observations and
controversies, we undertook a study to develop a
standardized assay for detecting antibodies to SQE
and to establish background levels, if any, for natu-
rally occurring antibodies to SQE.
In order to develop a reliable assay for antibodies to
SQE, we developed murine monoclonal antibodies to
SQE that could serve as a positive antibody control
(Matyas et al., 2000). Our original assay used 96 well
plates containing hydrophobic PVDF membranes. The
assay was highly reproducible, but was very labor
intensive. A new assay was developed that utilized
96 well polystyrene tissue culture plates (Matyas et al.,
2002). The assay had a high through-put capacity, was
reproducible and quantitative, and had increased sen-
sitivity. We now describe the adaptation of this latter
assay for the measurement of human antibodies to SQE
in cohorts of nonselected military and civilian popula-
tions, and in populations selected for their exposure to
numerous vaccines, including AVA.
2. Materials and methods
2.1. Materials
Squalene oil and bovine serum albumin (BSA)
(essentially fatty acid free; cat. # A-7030) were
purchased from Sigma-Aldrich, St. Louis, MO. Iso-
propanol (BAKER ANALYZEDR A.C.S. Reagent;
cat. # 9084-03) and casein were purchased from J.T.
Baker, Phillipsburg, NJ. Costar round bottom 96-well
sterile tissue culture plates (cat.# 3799) were pur-
chased from Corning, Corning, NY. FBS was from
GIBCO BRL Grand Island NY and was heated at 56
jC for 1 h prior to use. 10 Dulbecco’s PBS without
Ca2 + and Mg2 + was also purchased from Gibco BRL.
Human myelomas were purchased from the American
Type Culture Collection, Chantilly, VA and were
grown as described in the supplier’s instructions with
culture medium and additives from Gibco BRL. The
human antibody secreting myelomas were IM-9 (IgG
of unknown specificity obtained from a myeloma)
(Fahey et al., 1971), SA13 (IgG to tetanus toxoid)
(Larrick et al., 1986), 16M3F10 (IgG to diphtheria
toxoid) (Gigliotti et al., 1984), C5 (IgM to lipid A of
Gram negative bacteria (Teng et al., 1985), L612 (IgM
to gangliosides GM3 and GM4) (Irie, 1995) and
RPMI 1788 (IgM to tumor necrosis factor beta)
(Aggarwal et al., 1984). Mouse myeloma SQE #16,
which secretes a monoclonal antibody to SQE, was
grown as described (Matyas et al., 2000, 2002).
Human IgG and IgM and mouse IgM quantitation
kits were purchased from Bethyl Laboratories, Mont-
gomery, TX and were used on the culture super-
natants containing mAbs as per the enclosed
instructions. Affinity purified and adsorbed peroxi-
dase-linked sheep anti-human IgG (g-chain specific),
anti-human IgM, anti-mouse IgG (g-chain specific)
Fig. 1. Structure of squalene, cholesterol and polystyrene.
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and anti-mouse IgM were purchased from The Bind-
ing Site, San Diego, CA. ABTS substrate was pur-
chased from Kirkegaard and Perry Laboratories,
Gaithersburg, MD. Female BALB/c, B10.Br and
C57BL/6 mice were purchased from Jackson Labo-
ratories, Bar Harbor, ME. Retired breeder mice were
purchased at 10 months of age. Animal research was
conducted in compliance with the Animal Welfare
Act and other Federal statutes and regulations relating
to animals and experiments involving animals and
adheres to principles stated in the Guide for the Care
and Use of Laboratory Animals, NRC Publication,
1996 edition.
2.2. Volunteer population and serum preparation
Volunteers were recruited according to U.S. Army
regulations under human use protocols approved by
the Walter Reed Army Institute of Research and the
United States Army Medical Research Institute of
Infectious Diseases Human Use Review Committees
and the U.S. Army Human Subjects Research Review
Board. Written informed consent was obtained from
all volunteers prior to enrollment into the study. U.S.
Army human use guidelines were strictly adhered to
throughout the course of this study.
Three cohorts were studied. The first cohort con-
sisted of retired employees of the United States Army
Medical Research Institute of Infectious Diseases
(referred to as USAMRIID alumni). Most had re-
ceived numerous doses of AVA and other vaccines
through a USAMRIID special immunization program
(Pittman et al., 2002). All individuals (N = 40) were
greater than 58 years old (mean age 68; range 58–82;
87.5% male) and most had received multiple doses of
AVA (mean of 24 doses, range 0–47 doses). Three
individuals were not vaccinated with the anthrax
vaccine and the vaccine status of 3 others was
unknown. The second cohort was of similar age
(mean age 67; range 54–97; 61.8% male) from the
normal population of Frederick, MD. 372 individuals
were enrolled, and none had been vaccinated with
AVA. Blood was collected by standard clinical labo-
ratory methods and the serum was removed and
frozen at  80 jC.
For the third cohort, outdated fresh frozen plasma
was purchased from Camp Memorial Blood Center,
United States Army Medical Department Activities,
Fort Knox, KY. No donor information was provided
to the investigators of this study. However, the overall
donor population of the Fort Knox Blood Center is
comprised of 85% basic trainees, ranging in age from
17 to 21. Their immunization status with respect to
AVA administration is unknown. Pooled normal hu-
man serum, which on analysis was found to be
slightly positive for IgG and IgM antibodies to
SQE, was purchased from United States Biological,
Swampscott, MA. All of the above serum and plasma
were thawed, aliquoted and refrozen at  80 jC prior
to assay.
2.3. ELISA assay for antibodies to SQE in human
serum and plasma
SQE was diluted in ISP (0.2 Amol/ml; 9.6 Al SQE/
100 ml) and 0.1 ml (20 nmol) was placed in each well
of a Costar 96-well sterile round bottom tissue culture
plate. Control wells contained ISP alone. The plates
were placed in a biological safety cabinet and incubat-
ed overnight to allow the ISP to evaporate. PBS–0.5%
boiled casein, pH 7.4 (0.3 ml) was added to each well.
After incubation at room temperature for 2 h, the
buffer was removed and the plates were tapped on
paper towels to remove the residual blocker. Human
serum was diluted serially in PBS–0.5% casein start-
ing at a 1:25 dilution. Diluted serum (0.1 ml/well) was
added to the plate in triplicate. The plates were covered
with plastic wrap and incubated overnight at room
temperature. The plates were then washed 4 times with
0.5 ml/well of PBS, pH 7.4. Peroxidase-linked sheep
anti-human IgG (g-chain specific) and IgM (g-chain
specific) was diluted 1:1000 in PBS–0.5% casein and
0.1 ml/well was added to the plate. Following a 1-
h incubation at room temperature, the plates were
washed as described above. ABTS substrate (0.1 ml/
well) was added and the plates were incubated at room
temperature for 1 h. Absorbance was read at 405 nm.
Each plate contained culture supernatant from the C5
cell line, pooled normal human serum and blocking
buffer as controls. It should be noted that polystyrene
pipets, tubes, or other objects containing polystyrene,
should not be used in this assay. The use of polystyrene
caused high background (ISP) absorbances and greatly
increased the variability of the results. Highly purified
ISP also was required in order to ensure low back-
ground absorbances.
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2.4. ELISA assay for antibodies to SQE in mouse
serum
The assay was performed as described by Matyas
et al. (2002) with 10 nmol SQE per well. Briefly, the
mouse serum assay was similar to the human assay
except for the following: (1) PBS–3% BSA was
used as a blocker and diluent. (2) Culture superna-
tant from hybridoma SQE#16 containing a monoclo-
nal antibody to SQE was included as a positive
control on each plate. (3) Diluted mouse serum
was incubated for 1 h on the plates. (4) Peroxi-
dase-linked sheep anti-mouse IgG (g-specific) and
IgM (A-chain specific) (The Binding Site) were used
a secondary antibodies.
2.5. Interpretation of data and statistical analysis
Sera were judged to be positive for antibodies to
SQE if two dilutions (i.e., 1:25 and 1:50 dilutions for
human serum and 1:50 and 1:100 for mouse serum)
had absorbances that were greater than 3 times base-
line. Baseline was defined as the absorbance at which
the dilution curve became horizontal. Statistical anal-
yses were performed using Minitab Statistical Soft-
ware, Release 13 and StatXact, Version 5, Cytel
Software, Cambridge, MA. Continuous variables
were compared using t-tests, and categorical data were
compared using Pearson’s chi-squared tests. To esti-
mate the probability of antibodies to SQE, logistic
regression was used to assess the cohort effect adjust-
ed for the possible confounding effects of gender. The
between cohort odds ratios for IgG and IgM anti-
bodies to SQE were estimated.
3. Results
3.1. Effects of blocking agents on the ELISA
Several different blocking and diluent agents
were investigated for use in developing the ELISA
for human samples. In the absence of primary
antibody, either 0.5% casein (CASEIN) or 0.6%
gelatin (GEL/CASEIN) as blockers followed by
0.5% casein as the diluent, worked best for blocking
Fig. 2. Comparison of blocking and diluent agents on secondary antibody binding to control (ISP-treated) and SQE-coated wells (20 nmol/well).
Assays were conducted in PBS, pH 7.4 containing the blocker and diluent protein indicated. GEL/CASEIN wells were blocked in 0.6% gelatin
and the secondary antibody was diluted in 0.5% casein. All other samples were blocked and diluted in the protein buffer indicated. Values were
the mean of triplicate determinationsF standard deviation.
G.R. Matyas et al. / Journal of Immunological Methods 286 (2004) 47–67 51
of binding of the peroxidase-linked anti-human IgG
(Fig. 2A) and anti-human IgM (Fig. 2B) to the plate.
The binding of peroxidase-linked anti-human IgG
and anti-human IgM to SQE-coated wells was only
slightly elevated when 4% FBS was used as blocker
and diluent. Because we were concerned that the
SQE, which is known to be present in lipoprotein,
might inhibit the binding of anti-SQE antibodies to
SQE-coated wells, FBS was not considered for
further use. Based on these data, 0.5% casein was
chosen as the best diluent for human serum and the
secondary antibodies.
In order to determine the best blocking agent, wells
either were coated with SQE or not coated with SQE
(ISP treatment alone) and then blocked with 0.6%
gelatin or 0.5% casein. Human serum was diluted in
0.5% casein and plated on the wells A control human
monoclonal IgG (IM-9) did not bind to control (ISP-
treated) or SQE-coated wells when 0.6% gelatin or
0.5% casein were used as the blocking agent (Fig.
3A,B). 0.6% gelatin did not effectively block the
binding of human serum IgG antibodies to control
(ISP-treated) wells (Fig 3A). Absorbance values for
serum numbers 39, 43, 99, and 109 were >1.0, when
incubated on control wells. Furthermore, when 0.6%
gelatin was used as the blocker, the absorbance of
serum IgG antibodies binding to SQE-coated wells
was detectable, but was only slightly above that of
Fig. 3. Comparison of blocking agents on antibodies binding to control (ISP-treated) and SQE-coated wells (20 nmol/well). Wells were blocked
with PBS–0.6% gelatin (A, C) or PBS–0.5% casein (B, D). The serum and secondary antibodies were diluted in PBS–0.5% casein. Values
were absorbances from sera diluted 1:25 and assayed for IgG (A, B) and IgM (C, D) and are the mean of triplicate determinationsF standard
deviation. Culture supernatants of control human monoclonal antibodies IM-9 (IgG) and RPMI 1988 (IgM) were used at a concentration of
4 Ag/ml.
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control wells (Fig. 3A). In contrast, when 0.5% casein
was used as the blocker, the binding of serum IgG
antibodies to control wells was greatly reduced for all
sera studied (Fig. 3B). The absorbance for serum IgG
antibodies incubated on SQE-coated wells was readily
detectable when 0.5% casein was used as the blocker
(Fig. 3B). Consequently, 0.5% casein was used in all
further experiments for the measurement of IgG anti-
bodies to squalene in human serum.
Gelatin and casein were also tested as blocking
agents for the measurement of serum IgM antibodies to
SQE (Fig. 3C,D). Control human IgM monoclonal
antibody (RPMI 1788) did not bind to control (ISP-
treated) or SQE-coated wells with either the casein or
gelatin blocker (Fig. 3C,D). The absorbances for
serum containing IgM antibodies incubated on control
wells were essentially the same for gelatin and casein
blocked wells (Fig. 3C,D; open bars). However, the
absorbance of serum containing IgM antibodies incu-
bated on SQE-coated wells was dramatically higher
when the casein blocker was used than when gelatin
was used as a blocker (Fig. 3C,D; solid bars). Conse-
Fig. 4. Binding of serum anti-SQE antibodies as function of the amount of SQE added to the well. Wells were incubated with the amount of SQE
indicated in 100 Al of ISP. The ELISA was performed using the protocol described in Section 2 with PBS–0.5% casein as the blocker and
diluent. Values were the mean of triplicate determinationsF standard deviation.
G.R. Matyas et al. / Journal of Immunological Methods 286 (2004) 47–67 53
quently, casein was chosen as the preferred blocker for
the ELISA assay on human IgM antibodies to SQE.
3.2. Effect of the amount of SQE coated on the well
The binding of human serum antibodies to SQE-
coated wells was dependent upon the amount of
SQE (Fig. 4). Three types of binding curves were
observed. The first type had an optimal absorbance
range in which the absorbance increased with SQE,
reached a plateau, and then decreased (Fig. 4A,D).
The plateau region typically ranged from 5 to 50
nmol, but was dependent upon the serum assayed.
The second type was relatively independent of SQE
(Fig. 4B). The third type of curve continued to
increase in absorbance over the entire range of
SQE assayed (Fig. 4C). These 3 types of absorbance
curves were observed for both IgG and IgM. Since
Fig. 5. ELISA dilution curves from representative human sera assayed in two different experiments for IgG antibodies to SQE. Samples positive
of antibodies to SQE are serum #43 and 329. Samples negative for antibodies to SQE are serum #108 and 336. The ELISA assay was performed
using the protocol described in Section 2 with PBS–0.5% casein as the blocker and diluent. Values were the mean of triplicate
determinationsF standard deviation. Sera were judged to be positive for antibodies to SQE if two dilutions (i.e., 1:25 and 1:50) had absorbances
that were greater than 3 times baseline. Baseline was defined as the absorbance at which the dilution curve became horizontal.
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the absorbances at 20 nmol were high in all of the
serum assayed, 20 nmol was chosen as the optimal
amount of SQE to use for the detection of antibodies
to SQE in human serum.
3.3. Antibody binding to SQE in human cohorts
When serum samples were assayed for antibodies
to SQE, seven types of IgG (Fig. 5) or IgM (Fig. 6)
binding patterns were observed. (1) Sera were
positive for IgG antibodies to SQE (Fig. 5; sera
43, 329). Absorbances for serum IgG binding to
SQE-coated wells were elevated above control wells
at more than one dilution of serum. (2) Sera were
negative for IgG antibodies to SQE (Fig. 5; sera
108). Absorbances for serum IgG binding to SQE-
coated wells were not different from control wells,
which had very low absorbance (Fig. 5, serum 108).
Fig. 6. ELISA dilution curves from representative human sera assayed in two different experiments for IgM antibodies to SQE. Samples positive
for antibody to SQE are serum #43 and 119. Sample #357 has high background. Samples negative for antibodies to SQE are serum #100 and
335. The ELISA assay was performed using the protocol described in Section 2 with PBS–0.5% casein as the blocker and diluent. Values were
the mean of triplicate determinationsF standard deviation. Sera were judged to be positive for antibodies to SQE if two dilutions (i.e., 1:25 and
1:50 dilutions) had absorbances that were greater than 3 times baseline. Baseline was defined as the absorbance at which the dilution curve
became horizontal.
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(3) Absorbances for serum IgG binding to SQE-
coated wells were elevated at only the 1:25 dilution
(Fig. 5; serum 336) and were considered negative.
(4) Sera were positive for IgM antibodies to SQE
(Fig. 6; sera 43, 119). Absorbances for serum IgM
binding to SQE-coated wells were elevated above
serum IgM binding to control wells at more than
one dilution of serum. Absorbances on control wells
were approximately 50% of the absorbance of that
on the SQE-coated wells (Fig. 6; sera 43, 119). (5)
Sera contained high absorbance values for IgM
binding to both control and SQE-coated wells
(Fig. 6; serum 357). (6) Sera were negative for
IgM antibodies to SQE (Fig. 6; sera 100, 335).
Absorbances for serum IgM binding to SQE-coated
wells were not different from control wells, which
had very low absorbances. (7) Absorbances for
serum IgM binding to SQE-coated wells were
elevated at only slightly at the 1:25 dilution (not
shown) and therefore were considered negative.
Fig. 7. Effect of freeze– thaw on the ELISA dilution curves for antibodies to SQE from representative human serum samples. Serum was
obtained frozen, thawed and assayed. An aliquot was frozen at  70 jC overnight and assayed the next day. The ELISA assay was performed
using the protocol described in Section 2 with PBS–0.5% casein as the blocker and diluent and peroxidase-linked anti-mouse IgM as the second
antibody. Values were the mean of triplicate determinationsF standard deviation. Sera were from the USAMRIID alumni cohort #4 (A, B),
#5 (C, D), #21 (E, F) and the Frederick cohort #329 (G, H).
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3.4. Reproducibility of the assay
The assay was highly reproducible for both pos-
itive and negative responses for IgG (Fig. 5) and
IgM (Fig. 6) antibodies to squalene. Some sera were
assayed 3 times with similar results on each assay.
Slight differences were observed in the absorbances
for positive responses from assay to assay, but
positive response were always positive (Fig. 5;
serum 43, 329). High absorbances on control wells
also were highly reproducible (Fig. 6; serum 43,
357). Freeze–thaw had no effect on the measurement
of antibodies to squalene (Fig. 7). Positive samples
remained positive after freeze–thaw with approxi-
mately the same dilution curve (Fig. 7A–F) and
negative samples remained negative (Fig. 7G–H).
The absorbances on control wells also were not
affected by freeze–thaw.
3.5. Prevalence of antibodies to SQE in human sera
To establish a basis for comparison of the preva-
lence of antibodies to SQE in different cohorts, we
defined what constitutes a positive result: A serum
sample was scored as positive if it had absorbances
greater than 3 times baseline at two dilutions. Dilu-
tions consisted of 1:25, 1:50, 1:100, 1:200, 1:400 and
1:800. As shown in Table 1, 42.6% of the sera assayed
from the cohort from Frederick, MD were positive for
IgG or IgM antibodies to SQE. The predominant
antibody to SQE was IgM, which was two-fold greater
than IgG (Table 1). Only 4.9% of the sera assayed
from the Frederick cohort were positive for both IgG
and IgM antibodies to SQE.
The Frederick cohort served as a control cohort of
similar aged individuals for the USAMRIID alumni
cohort. None of the individuals in the Frederick cohort
had been employees at USAMRIID. There were no
significant differences between these two cohorts in
the prevalence of antibodies to SQE (Table 1, 95%
confidence interval). There is a two-fold difference in
the prevalence of IgG antibodies to SQE observed in
the USAMRIID alumni (7.5%) and Frederick cohorts
(15.1%), but this difference is not statistically signifi-
cant (v(1)
2 = 1.69, p = 0.19). IgM antibodies to SQE
were 37.5% and 32.3% for the USAMRIID and
Frederick cohorts, respectively (v(1)
2 = 0.43, p = 0.51).
Forty percent of the sera from the USAMRIID alumni
were positive for IgG or IgM antibodies to SQE
compared with 42.6% from the Frederick cohort
(Table 1) (v(1)
2 = 0.10, p = 0.75). Only 5% of the sera
from the USAMRIID alumni and 4.9% of the Fred-
erick cohort had both IgG and IgM antibodies to SQE
(Table 1) (v(1)
2 = 0.00, p = 0.97).
Of the 299 samples from the Fort Knox blood bank
cohort, only 19.4% were scored as positive for anti-
bodies to SQE (Table 1). Compared to the samples
from the Frederick cohort, the samples from the blood
bank at Fort Knox had a significantly reduced prev-
alence of antibodies to SQE (Table 1; 95% confidence
interval). The most pronounced difference between
the two cohorts was in IgG antibodies to SQE. There
were no detectable IgG antibodies to SQE in the
samples from the Fort Knox blood bank compared
with 15.1% in the Frederick cohort (Table 1)
(v(1)
2 = 49.25, p < 0.0001). The incidence of IgM anti-
bodies to SQE was also significantly reduced in the
Fort Knox Blood Bank cohort (19.4%) compared to
Table 1
Frequency of antibodies to SQE in human serum
Antibody SQE-coated wells (percent positive) Wells lacking SQE (percent positive)
type
USAMRIID
(N= 40)
Frederick
(N= 372)
Fort Knox
(N = 299)
USAMRIID
(N= 40)
Frederick
(N = 372)
Fort Knox
(N= 299)
IgG 7.5 [1.6–20.4]a 15.1 [11.6–19.1] 0.0 [0.0–1.0] 0.0 0.5 0.0
IgM 37.5 [22.7–54.2] 32.3 [27.4–37.4] 19.4 [15.1–24.3] 2.5 7.3 13.0
IgG or IgM 40.0 42.6 19.4 2.5 7.8 13.0
IgG and IgM 5.0 4.9 0.0 0.0 0.0 0.0
Sera having absorbances of >3 times baseline on SQE-coated wells or wells lacking SQE (ISP-treated) at the 1:25 and 1:50 dilutions were
scored as positive.
a 95% confidence intervals for binomial proportions.
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the Frederick cohort (32.3%) (Table 1) (v(1)
2 = 14.23,
p = 0.0002). It should be noted that the estimated
average age of the Fort Knox cohort (age range 17–
21) was considerably lower than the Frederick control
or USAMRIID cohorts (mean 68, age range 58–82).
The titers of the positive samples in each of the
three cohorts were generally low. Only one serum
sample was positive both for IgG and IgM at the
1:100 dilution in the USAMRIID alumni. In this one
serum sample, the endpoint titers were 100 for the
IgG and 400 for the IgM. There was only one positive
IgG serum sample out of 372 at the 1:100 dilution in
the Frederick cohort, and that serum had an endpoint
titer of 400. There were 27 positive IgM samples at
the 1:100 dilution in the Frederick cohort. Titers
ranged from 100 to 1600, with 12 samples having
endpoint titers of 100, 4 samples having endpoint
titers of 200, 3 samples having endpoint titers of 400,
and 1 each with endpoint titers of 800 and 1600. Only
three of the samples from the Fort Knox cohort had
IgM endpoint titers z 100, with titers of 100, 200 and
400, respectively.
3.6. Antibodies to SQE in USAMRIID alumni who
received anthrax vaccine
As a condition for employment most of the
USAMRIID employees were vaccinated with anthrax
vaccine AVA before access was granted to biocontain-
ment laboratories where Bacillus anthracis was stud-
ied. Most of the USAMRIID alumni received several
other vaccines as well as AVA through the USAM-
RIID special immunization program (Pittman, 2002).
Six of the 40 individuals in the cohort were not
vaccinated or the AVA vaccination status was un-
known, and all 6 have been removed from analysis
in this section. One of the latter six samples removed
from analysis was positive for IgG to SQE and two
out of six were positive for IgM (Table 2). The mean
number of doses of AVA that had been administered to
the remaining individuals was 26 (range 3–47 doses)
(Table 2). After removal of the six samples, the
prevalence of antibodies to SQE was basically un-
changed from that shown in Table 1 for the USAM-
RIID alumni. 5.7% were positive for IgG or both IgG
and IgM antibodies to SQE. 37.1% were positive for
IgM alone or IgG or IgM antibodies to squalene.
There were no statistical differences between the
USAMRIID alumni who received AVA and the con-
trols of similar ages from Frederick (IgG—v(1)
2 = 2.3,
p = 0.13; IgM—v(1)
2 = 0.33, p = 0.56; IgG or IgM—
v(1)
2 = 0.39, p = 0.53). Analyses of the health informa-
tion from the USAMRIID alumni revealed no obvious
relationship between the health of the individuals and
antibodies to SQE. Many of the individuals in both
the USAMRIID and the Frederick control cohorts did
Table 2
Age, sex, AVA doses, and antibodies to SQE among the USAMRIID
alumni
ID no. Age Sex AVA #
doses
SQE
IgG
SQE
IgM
1 59 M 3 0 0
2 66 M 33 0 0
3 63 F 0 0 0
4 82 F 31 Pos Pos
5 68 M Unknown 0 Pos
6 71 M 4 0 0
7 69 F 0 0 Pos
8 59 M 37 0 Pos
9 72 M 25 0 0
10 70 M Unknown Pos 0
11 66 M 47 Pos Pos
12 65 M 16 0 0
13 79 M 27 0 Pos
14 70 M 0 0 0
15 Unknown M 41 0 0
16 60 M 24 0 0
17 74 M 39 0 Pos
18 59 M 14 0 0
19 65 M 40 0 Pos
20 75 M 28 0 0
21 68 M 20 0 Pos
22 69 M 15 0 0
23 64 F 8 0 Pos
24 72 M 32 0 Pos
25 70 M 31 0 Pos
26 61 F 8 0 0
27 71 M 30 0 0
28 58 M 26 0 0
29 Unknown M 35 0 0
30 70 M 36 0 0
31 76 M 36 0 0
32 78 M 33 0 0
33 67 M 27 0 0
34 71 M 29 0 0
35 59 M Unknown 0 0
36 64 M 14 0 0
37 71 M 45 0 Pos
38 Unknown M 9 0 Pos
39 70 M 24 0 0
40 72 M 20 0 Pos
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have various illnesses or chronic diseases, but this was
expected to be the case for any cohort from the
general population with an average age of approxi-
mately 68 and an age range of 58–82.
3.7. Increased prevalence of antibodies to SQE in
women
The Frederick cohort contained 230 males and 142
females. There were 35 males and 5 females in the
USAMRIID cohort. The data from these two cohorts
were combined for analysis of the effect of sex on the
prevalence of antibodies to SQE. Thus, there were
265 males and 147 females enrolled in the study.
Thirty-three (12.5%) of the male samples and 26
(17.7%) of the female samples were positive for IgG
antibodies to SQE. There was no statistical difference
in the prevalence of IgG antibodies to SQE between
males and females (v(1)
2 = 2.07, p = 0.15). However,
there was a statistically significant increase in preva-
lence of IgM antibodies to SQE in females as com-
pared to males. Seventy-five (28.4%) of the male
samples and 60 (40.8%) of the female samples were
positive (v(1)
2 = 6.72, p = 0.01). Female subjects were
1.75 times more likely to be positive for IgM anti-
bodies to SQE (95% confidence interval on the odds
ratio: lower limit = 1.14, upper limit = 2.66). Similarly,
females were 1.67 times more likely to be positive for
IgG or IgM antibodies to SQE (95% CI on the odds
ratio: 1.11,2.51). There were 100 (37.7%) samples
from males and 74 (50.3%) samples from females
having either IgG or IgM antibodies to SQE
(v(1)
2 = 6.16, p = 0.013). In order to ensure that this
observed increase in prevalence of antibodies to SQE
in females did not alter the conclusions drawn from
the comparison of the USAMRIID and Frederick
cohorts as homogeneity of Odds Ratio test was con-
ducted. There was a common odds ratio across gender
and it was concluded that no effect modification
occurred due to the differences in gender distribution
between the two cohorts.
3.8. Antibody binding to wells lacking SQE
In assaying sera for antibodies to SQE, absor-
bances to wells lacking SQE served as controls.
Fig. 8. Culture supernatants containing human monoclonal antibodies were assayed by ELISA for reactivity to SQE or polystyrene. The ELISA
assay was performed using the protocol described in Section 2 with PBS–0.5% casein as the blocker and diluent. Values were the mean of
triplicate determinationsF standard deviation. Panel Awas IM-9, which secreted an IgG antibody of unknown specificity cloned from a human
myeloma (Fahey, 1971). Panel B was 16M3F10, which secreted an IgG antibody to diphtheria toxoid) (Gigliotti, 1984). Panel C was SA13,
which secreted an IgG antibody to tetanus toxoid) (Larrick, 1986). Panel D was L612, which secreted an IgM antibody to the gangliosides GM3
and GM4 (Irie, 1995). Panel E was C5, which secreted an IgM antibody to lipid A of Gram negative bacteria (Teng, 1985). Panel F was RPMI
1788, which secreted an IgM antibody to tumor necrosis factor beta (Aggarwal, 1984).
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However, upon examination of all of the human
samples assayed (N = 711), absorbances for IgM
antibodies binding to control wells were elevated
at the 1:25 and 1:50 dilutions in 32.5% and 9.4%,
of the samples, respectively. In contrast, only 2.9%
(1:25 dilution) and 0.3% (1:50 dilution) of the
samples assayed were elevated for IgG antibodies
binding to control wells. Overall, these elevations
typically were approximately 50% of the absorbance
levels observed for binding to SQE-coated wells
(Fig. 6; sera 43 and 119). In a small number of
samples, the absorbances for control wells were
almost equal to the absorbance for SQE-coated
wells (Fig. 6; serum 357). These elevations in
absorbance in control wells lacking SQE were
invariably observed only in samples which also
were scored as positive for antibodies to SQE.
When culture supernatants containing human mono-
clonal IgG or IgM antibodies to other antigens were
assayed in the SQE ELISA, no binding was
detected either to control or SQE-coated wells
(Fig. 8A–D,F), except for the antibody from the
clone that secretes an IgM antibody to lipid A (Fig.
8E). This latter monoclonal antibody bound to SQE-
coated wells, but not to control wells.
The binding of the latter monoclonal anti-lipid A
antibody to SQE was approximately 10% of the
binding of the antibody to lipid A (data not shown).
The above data suggest that antibody binding to
control wells was not due to a nonspecific interaction
between the polystyrene well and the antibody. Al-
though the precise region of cross-reactivity of the
anti-lipid A monoclonal antibody between lipid A and
SQE is unknown, several possible regions of similar-
ity could be identified. In any case, the existence of
the binding specificity to SQE by this human mono-
clonal antibody permitted its use as a positive control
for standardizing and validating the assays with un-
known human serum samples.
In order to investigate the nature of the elevated
absorbance on control wells, diluted serum was
plated on ISP-treated wells lacking SQE, or on
SQE-coated wells, to adsorb the antibodies. After
two rounds of adsorption, the supernatant was placed
on ISP-treated wells lacking SQE or on SQE-coated
wells, followed by ELISA. Two rounds of absorption
Fig. 9. Effect of pre-incubation of serum on control (ISP-treated) or SQE-coated wells on the binding to control or SQE-coated wells. Sera was
diluted in PBS–0.5% casein and plated on 96-well plates treated with ISP or coated with SQE. Following incubation for 2 h at room
temperature, the contents of the wells were transferred to a new plate containing wells treated with ISP or SQE. Following incubation overnight
at room temperature, the supernatant were removed and assayed by the standard ELISA for IgM antibodies to SQE. Unabsorbed sera (circles)
were serum samples assayed by ELISA without prior adsorption. Values were the mean of triplicate determinationsF standard deviation.
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removed both the polystyrene and SQE binding
activities from serum 243 (Fig. 9A). Absorption on
ISP-treated control wells lacking SQE greatly dimin-
ished the binding of serum 357 to SQE-coated wells
(Fig. 9B).
3.9. Antibodies to SQE in mouse serum
IgG and IgM antibodies to SQE were not observed
in the individual sera of 2-month-old mice in any of
the strains studied (Table 3). However, many individ-
ual mice developed either IgG or IgM antibodies to
SQE as a function of time (Table 3). The degree of
tendency to develop antibodies was strain specific:
C57BL/6>B10.BR>/BALB/c.
The incidence of IgG antibodies to SQE was
100% at 18–19 months of age for the C57BL/6
mice. B10.Br had a maximal incidence of 85% at 18
months of age. This incidence decreased for both
strains, with none of the B10.Br mice testing posi-
tive, and 46% for the C57BL/6 mice testing positive,
at 24 months of age. Ninety-five and 100% of
B10.Br and C57BL/6 mice, respectively, tested pos-
itive for IgG antibodies to SQE some time during the
course of the experiment. Only a low incidence of
IgG antibodies to SQE was observed in the serum of
BALB/c mice, and low absorbances with positive
sera were only slightly above 3 times baseline.
Although 35% of BALB/c mice tested positive for
IgG antibodies to SQE at some time in the course of
the experiment, this only occurred at one time point
for each positive mouse.
As with IgG antibodies, IgM antibodies to SQE
were not observed in the serum from mice at 2 months
of age (Table 3). The prevalence of mouse serum
testing positive for IgM antibodies to SQE increased
with the age of the mice in all three strains assayed.
There was a higher incidence of IgM antibodies to
SQE in the BALB/c and C57BL/6 stains as compared
to the B10.Br mice, and the IgM antibodies to SQE
were observed earlier in the BALB/c and C57BL/6
mouse sera than the B10.Br mouse sera. Only 65% of
the B10.Br mice were positive for IgM antibodies to
SQE sometime during the experiment. In contrast,
Table 3
Appearance of antibodies to SQE in mouse serum as function of age
Age (months) BALB/c % positive (# positive/total)
[95% confidence interval]
B10.Br % positive (# positive/total)
[95% confidence interval]
C57BL/6 % positive (# positive/total)
[95% confidence interval]
IgG IgM IgG IgM IgG IgM
2a 0 (0/49)
[0.0–5.9]
0 (0/60)
[0.0–4.9]
0 (0/25)
[0.0–11.3]
0 (0/25)
[0.0–11.3]
0 (0/25)
[0.0–11.3]
0 (0/25)
[0.0–11.3]
10 11 (2/18)
[1.4–34.7]
32 (6/19)
[12.6–56.6]
0 (0/18)
[0–15.3]
10.5 (2/19)
[1.3–33.1]
12 (2/17)
[1.5–36.4]
30 (6/20)
[11.9–54.3]
16 10 (2/19)
[1.3–33.1]
37 (7/19)
[16.3–61.6]
10 (2/20)
[1.2–31.7]
0 (0/20)
[0.0–13.9]
74 (14/19)
[48.8–90.9]
90 (18/20)
[68.3–98.8]
17 0 (0/19)
[0.0–14.6]
63 (12/19)
[38.4–83.7]
5 (1/20)
[0.1–24.9]
5 (1/20)
[0.1–24.9]
65 (13/20)
[40.8–84.6]
80 (16/20)
[56.3–94.3]
18 N.D. 39 (7/18)
[17.3–64.3]
85 (17/20)
[62.1–96.8]
5 (1/20)
[0.1–24.9]
100 (17/17)
[83.8–100]
89 (16/18)
[65.3–98.6]
19 6 (1/17)
[0.1–28.7]
65 (11/17)
[38.3–85.8]
60 (12/20)
[36.1–80.9]
25 (5/20)
[8.7–49.1]
100 (18/18)
[84.7–100]
72 (13/18)
[46.5–90.3]
21 10 (1/10)
[0.3–44.5]
62 (8/13)
[31.6–86.1]
45 (9/20)
[23.1–68.5]
55 (11/20)
[31.5–76.9]
94 (16/17)
[71.3–99.9]
62 (10/16)
[35.4–84.8]
24 17 (1/6)
[0.4–64.1]
86 (6/7)
[42.1–99.6]
0 (0/17)
[0.0–16.2]
50 (9/18)
[26.0–74.0]
46 (6/13)
[19.2–74.9]
58 (7/12)
[27.7–84.8]
At any
time point
35 (7/20) 85 (17/20) 95 (19/25) 65 (13/20) 100 (20/20) 100 (20/20)
Mice were bled at the time intervals indicated and the sera were assayed for antibodies to SQE. Serum was scored as positive for IgG or IgM
antibodies to SQE if the absorbance was >3 times the baseline at both the 1:50 and 1:100 dilutions. Baseline absorbances ranged from 0.1 to
0.18 in different assays.
a Sera from 2 month old mice were from different animals than the retired breeders used for the remaining time points.
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85% and 100% of BALB/c and C57BL/6 mice,
respectively, developed IgM antibodies to SQE.
Although the data in Table 3 is not designed to
illustrate the titers of the IgG or IgM antibodies to
SQE, endpoint titers (absorbance >3 times assay
baseline) of positive samples, when examined in
detail, were typically 100–400. However, a small
number of samples were observed to have positive
absorbances at a 1:800 dilution (highest dilution
assayed). There were three types of individual animal
responses for antibodies to SQE. (1) Animals were
negative for IgG or IgM antibodies to SQE (Fig.
10A,C,D). (2) Animals were initially negative for
antibodies to SQE and later developed antibodies to
SQE which remained elevated (Fig. 10B,E–H). (3)
Animals were initially negative or slightly positive for
antibodies to SQE developed higher titers to anti-
bodies to SQE and then became negative for anti-
bodies to SQE at later time points (Fig. 10I–J). There
was no observed relationship between IgG and IgM
Fig. 10. Occurrence of naturally occurring antibodies to squalene in mice as function of age. Each panel represents a different mouse. Panels A
and B are IgG and panels C–J are IgM. Values were the mean of triplicate determinationsF standard deviation of the serum diluted 1:100.
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antibodies to SQE. Twenty-two animals died during
the course of the experiment with the deaths occurring
after 17 months of age. Most of the deaths occurred in
the BALB/c mice. There appeared to be no relation-
ship between antibodies to squalene and death. As
with the human serum, some of the mouse sera had
elevated absorbances on control wells. This was
observed for both IgG and IgM antibodies (Fig. 10).
4. Discussion
A highly reproducible, high throughput, and quan-
titative assay for measuring antibodies to SQE in
human serum is described. The assay was modified
from our previously described assay for murine anti-
bodies to SQE (Matyas et al., 2002). Like the mouse
assay, the human assay used Costar tissue culture 96
well plates, which were plates that are not routinely
used for ELISA assay. As with murine antibodies to
SQE, none of the standard ELISA plates were useful
for this human SQE antibody assay (data not shown).
The use of the standard ELISA plates resulted in high
background absorbances in control (ISP-treated)
wells.
The murine assay used BSA as a blocker/diluent.
However, BSA did not effectively block the binding
of peroxidase-linked anti-human IgG and IgM to
SQE-coated plates. Casein effectively blocked this
non-specific binding in the human assay. The optimal
amount of SQE added to the plates was similar for
both the human and mouse assays. The human assay
used 20 nmol of SQE and the mouse assay used 15
nmol. The quantification of the amount of SQE bound
to the wells under the conditions used in the human
antibody assay was virtually identical to that de-
scribed for the mouse (Matyas et al., 2002). In the
mouse assay, the primary serum was incubated on the
assay plate for 1 h. Early experiments during assay
development suggested that an increased incubation
time (overnight) increased the sensitivity of the assay
for human antibodies. The optimal dilution of the
secondary antibody was determined to be 1:1000
(data not shown). There were no differences observed
with different lots of plates (data not shown).
Elevated absorbances were observed on control
wells of some of the samples testing positive for
antibodies to SQE in both the human and mouse
serum (Figs. 3D; Fig. 5-sample 43; 6-samples 43,
119 and 357; 7C,D; and 10B,E,G,H,I,J). This was
most prevalent for IgM antibodies at 1:25 and 1:50
dilutions for the human and mouse samples, respec-
tively. This was not a result of the ISP treatment itself,
since similar results were obtained when control wells
were untreated. Furthermore, only 32.5% of the hu-
man samples that were positive for antibodies to SQE
had elevated absorbances on control wells. With any
given serum, absorbance in the control wells never
exceed those found in the SQE-coated wells.
We hypothesize that the above binding of SQE-
positive serum samples to the control wells was due to
cross-reactivity of SQE antibodies to polystyrene.
This is supported by the following pieces of evidence.
(1) None of the samples that tested negative for
antibodies to SQE from humans or mice had elevated
absorbances on control wells. (2) As shown in Fig. 8,
human monoclonal IgG or IgM antibodies did not
bind nonspecifically to control wells (ISP-treated).
Two additional antibodies, one IgG and one IgM
(not shown), were also assayed and no reactivity
was observed to control wells or SQE-coated wells.
Similarly, control murine monoclonal antibodies (six
IgM antibodies) did not have elevated absorbances on
control wells (Matyas et al., 2000, 2002; data not
shown). (3) Pre-incubation of serum for two rounds
on ISP-treated wells removed not only the absorbance
seen on control wells, but also effectively all of the
SQE binding activity (Fig. 9). Thus, it appears that the
binding to control wells was a specific binding of IgG
and IgM antibodies to the wells. (4) Polystyrene is a
polymer of styrene (CH2 =CH–C6H6) (Fig. 1), and
sterilization of the cell culture plates by gamma
irradiation can lead to cleavage of one or more of
the double bonds in the benzyl rings and the hydro-
carbon backbone. Gamma irradiation may also induce
fusion of the benzyl rings. Consequently, irradiated
polystyrene may have elements that are structurally
similar to SQE in that irradiated polystyrene has open
ring structures that still contain double bonds. One
interesting possibility may be that the observed anti-
bodies to SQE may be antibodies to polystyrene that
cross-react with SQE. Styrene is a widespread envi-
ronmental contaminant that is particularly derived
from cigarette smoke or is present in food after having
been leached from polystyrene food containers, espe-
cially containers containing yoghurt or fat products
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(Newbook and Caldwell, 1993). Although we have no
direct evidence for the induction of antibodies to
styrene or polystyrene, the structural similarities of
styrene and polystyrene with SQE (Fig. 1) raise this as
a hypothetical possibility.
Sera from three human cohorts were assayed for
antibodies to SQE. Antibodies to SQE were detected
in some of the samples in all three cohorts. The
volunteers from Frederick were an age-restricted co-
hort from Frederick, MD. The presence of antibodies
to SQE in this cohort implies that antibodies to SQE
are a naturally occurring phenomenon in humans.
This is not surprising, since previous studies have
demonstrated naturally occurring human antibodies to
cholesterol (Alving et al., 1989) and to phospholipids
(Alving, 1984). Naturally occurring antibodies to
cholesterol have been found in essentially 100% of
volunteers studied (Alving and Wassef, 1999). Anti-
bodies to cholesterol do not appear to have an adverse
impact on health and may play a role in the regulation
of LDL (Alving and Wassef, 1999). Since SQE is
present on LDL particles in plasma, it is possible that
naturally occurring antibodies to SQE may also con-
tribute to the regulation of LDL.
Although no IgG antibodies to SQE were detected
in the sera from the Fort Knox cohort, 7.5 and 15.1%
of the samples from the USAMRIID alumni and
Frederick cohorts, respectively, were positive for
IgG antibodies. With respect to IgM, the samples
from the USAMRIID alumni and the Frederick
cohorts were 37.5% and 32.3% positive, respectively,
while the Fort Knox samples were 19.4%. It should be
noted that there is a 9.3-fold difference between the
number of volunteers in the USAMRIID alumni
(N = 40) and the Frederick cohort (N = 372). The low
number of volunteers in the USAMRIID alumni
greatly reduced the power to determine significant
differences between the two cohorts. Unfortunately,
we were unable to obtain additional volunteers in the
USAMRIID alumni cohort. The samples from the
USAMRIID alumni and the Frederick cohorts were
from volunteers >58 years old. Compared to the
Frederick cohort, the prevalence of both IgG and
IgM antibodies to SQE was significantly reduced in
the Fort Knox cohort. Although no individual age
information was available from the volunteers of the
Fort Knox cohort, the demographics of the volunteer
population at the Camp Memorial Blood Center, Fort
Knox (85% of the individuals are 17–20 years of age)
suggested to us that antibodies to SQE may increase
as a function of age.
There are numerous circumstances in which natural
antibodies are related to age. One example of this is
that reported by Pinto and Rimon (1970) that demon-
strated the presence of antibodies to hydrocortisone
hemisuccinate in 26% of the serum samples from
normal human adults aged 25–65; but in only 3%
of infants 9 months–3 years of age. In support of this
hypothesis, we found that young mice (2 months old)
had no antibodies to SQE. Ten-month-old mice had a
10–30% incidence of antibodies to SQE. The inci-
dence increased as a function of age, with 100% of the
C57BL/6 mice testing positive for antibodies to SQE
at 18 and 19 months of age. This mouse study also
demonstrated that antibodies to SQE developed natu-
rally without vaccination with AVA or other vaccines.
The development of antibodies to SQE varied with the
strain of the mouse, thus suggesting that genetic
factors may also be involved.
Thirty-four volunteers from the USAMRIID alumni
cohort had been immunized with the anthrax vaccine
AVA. Most had received numerous vaccinations
(mean = 26 doses, range 3–47 doses). Comparison of
the AVA-immunized USAMRIID alumni with the
similar aged cohort from the normal population of
Frederick, none of whom received AVA, revealed that
immunization with AVA did not significantly increase
the prevalence of antibodies to SQE (IgG—v(1)
2 = 2.3,
p = 0.13; IgM—v(1)
2 = 0.33, p = 0.56; IgG or IgM—
v(1)
2 = 0.39, p = 0.53). Although not significant, the
prevalence of IgG antibodies to SQE in the AVA
immunized group (5.1%) was approximately threefold
less than the unimmunized Frederick control group.
Asa et al. (2002) also found that there was no statistical
difference in the incidence of antibodies to SQE
between AVA immunized and unimmunized individu-
als. They also reported a 15.8% prevalence of IgG
antibodies to SQE in their controls, which was similar
to the 15.1% prevalence of IgG antibodies to SQE in
the Frederick cohort. However, no IgG antibodies to
SQE were observed in the Fort Knox cohort. Asa et al.
(2002) did not report the age of their control popula-
tion, but in our study the control group had a similar
age distribution to that of the AVA immunized group.
The existence of naturally occurring antibodies to
SQE raises the issue of whether such antibodies are
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produced as a result of immunization with SQE (for
example, SQE present as a contaminant of AVA), or
by immunization with a substance similar to SQE in
the environment that might induce cross-reacting anti-
bodies. Induction of antibodies to SQE by SQE
contaminants of AVA or other vaccines seems highly
unlikely. Using an HPLC assay with a detection limit
of 70 ng/ml, Spanggord et al. (2002) reported that
squalene was not present in 17 different lots of AVA.
However, the FDA provided written testimony to
Congress that several lots of AVA and several other
vaccines had squalene contamination in the ‘‘low
parts per billion’’ (ng/ml) as detected by gas chroma-
tography (Metcalf, 2000). The data from which these
latter determinations were not provided to Congress,
nor were the experiments published in the scientific
literature, making the scientific validity of the testi-
mony difficult to evaluate. However, even if the FDA
data were correct and an individual was given 10 ng
of SQE in an AVA dose, it is difficult to believe that
this minute amount of SQE contaminant could induce
antibodies to SQE. We previously reported an inabil-
ity to induce antibodies to SQE in mice with multiple
immunizations with large amounts of SQE alone or
mixed with alum and other potent adjuvants and
immuno-stimulatory formulations (Matyas et al.,
2000). Only with two of eight formulations were
low to moderate titers of IgM antibodies to SQE
observed. No IgG antibodies to SQE were observed.
Furthermore, the amount of SQE present as an infin-
itesimal contaminant in vaccines or other injectables
pales by comparison with the huge amounts of SQE
that are normally continually synthesized and that are
present in skin and liver, and normally circulating in
blood. It has been hypothesized that naturally occur-
ring antibodies to cholesterol might be derived from
inflammatory processes involving the skin (Alving
and Wassef, 1999), and antibodies to SQE might be
derived in a similar manner.
Although increased prevalence of natural antibod-
ies is often seen in the serum of women, increased
prevalence of antibodies to SQE was an unanticipat-
ed finding in the present study. However, this in-
creased prevalence of antibodies to SQE in females
did not alter the conclusions drawn between the
Frederick and USAMRIID (and AVA subcohort),
since the crude and gender adjusted odds ratios
estimated using logistic regression for IgG, IgM
and IgG or IgM antibodies to SQE were not signif-
icant. It is unclear as to the reasons for this increased
prevalence in women. One possibility may be that
some women may have developed antibodies to
steroid sex hormones such as progesterone, testos-
terone or estrogens and that these antibodies may
cross-react with SQE. Antibodies to estradiol (Cou-
nihan et al., 1991), 16-a-hydroxyestrone (Bucala et
al., 1987) and ethinylestradiol (Beaumont et al.,
1989) were reported in sera from women who used
oral contraceptives or had systemic lupus erythema-
tosus. Patients with systemic lupus erythematosus
also were reported to have antibodies to h-estradiol
(Mionuddin, 1998). Antibodies to testosterone have
been reported in a woman with hypergonadotropic
hypogonadism (Kuwahara et al., 1998). Furthermore,
using human lymphocyte-derived DNA libraries,
antibodies to digoxigenin, estradiol, testosterone
and progesterone were found (Dorsam et al., 1997).
Since the steroid sex hormones are synthesized from
cholesterol (which, in turn, is synthesized from SQE)
and since they have the fused cholesterol ring
structure, antibodies to these hormones may cross-
react with SQE. Murine monoclonal antibodies to
steroid hormones have been extensively studied
(Franek, 1987; Grover and Odell, 1977). They gen-
erally cross-reacted to varying degrees with a small
number of other steroid hormones (Fantl and Wang,
1984; Mais et al., 1995; Brochu et al., 1984).
Limited analysis of the specificity of our murine
monoclonal antibodies to SQE (Matyas et al., 2000,
2002) indicated that some of the clones cross-reacted
with cholesterol and/or testosterone (unpublished
data).
In summary, we have described a highly reproduc-
ible, high throughput, and quantitative assay for
measuring antibodies to SQE in human serum. Using
this newly developed assay, both naturally occurring
IgG and IgM antibodies to SQE were observed in
human serum. The antibody titers were generally low.
There was an increased prevalence of antibodies to
SQE in serum from females as compared to males.
There was no correlation between the presence of
antibodies to SQE and previous immunization with
AVA. The data further suggested that the prevalence
of antibodies to SQE in human serum increased with
the age of the volunteer. Longitudinal studies in three
different strains of mice confirmed the presence of
G.R. Matyas et al. / Journal of Immunological Methods 286 (2004) 47–67 65
naturally occurring IgG and IgM antibodies to SQE
and the prevalence of antibodies to SQE increased
with the age of the mice.
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